Rifamycin Derivatives Are Effective Against Staphylococcal Biofilms In Vitro and Elutable From PMMA

Clinical Orthopaedics and Related Research

Volumn 473, Issue 9, 2015, Pages 2874-2884

  Sanchez, Carlos J ^a   Shiels, Stefanie M ^a   Tennent, David J ^a   Hardy, Sharanda K ^a   Murray, Clinton K ^b   Wenke, Joseph C ^a  

^a US ARMY INSTITUTE OF SURGICAL RESEARCH   (United States)

^b SAN ANTONIO MILITARY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFAZOLIN; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; GENTAMICIN; OXACILLIN; POLY(METHYL METHACRYLATE); RIFABUTIN; RIFAMPICIN; RIFAMYCIN DERIVATIVE; RIFAPENTINE; RIFAXIMIN; VANCOMYCIN; ANTIINFECTIVE AGENT; DRUG CARRIER; RIFAMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BIOASSAY; BIOFILM; CELL VIABILITY; CONTROLLED STUDY; DRUG RELEASE; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; CHEMISTRY; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECTS; EVALUATION STUDY; GROWTH, DEVELOPMENT AND AGING; KINETICS; MEDICINAL CHEMISTRY; MICROBIAL SENSITIVITY TEST; SOLUBILITY;

ANTI-BACTERIAL AGENTS; BIOFILMS; CHEMISTRY, PHARMACEUTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; KINETICS; MICROBIAL SENSITIVITY TESTS; POLYMETHYL METHACRYLATE; RIFAMYCINS; SOLUBILITY; STAPHYLOCOCCUS AUREUS;

EID: 84938551847     PISSN: 0009921X     EISSN: 15281132     Source Type: Journal    
DOI: 10.1007/s11999-015-4300-3     Document Type: Article

References (60)

1. Akers KS, Mende K, Cheatle KA, Zera WC, Yu X, Beckius ML, Aggarwal D, Li P, Sanchez CJ, Wenke JC, Weintrob AC, Tribble DR, Murray CK, Infectious Disease Clinical Research Program Trauma Infectious Disease Outcomes Study Group. Biofilms and persistent wound infections in United States military trauma patients: a case-control analysis. BMC Infect Dis. 2014;14:190.
2. Anguita-Alonso P, Rouse MS, Piper KE, Jacofsky DJ, Osmon DR, Patel R. Comparative study of antimicrobial release kinetics from polymethylmethacrylate. Clin Orthop Relat Res. 2006;445:239–244.
3. Antunes AL, Trentin DS, Bonfanti JW, Pinto CC, Perez LR, Macedo AJ, Barth AL. Application of a feasible method for determination of biofilm antimicrobial susceptibility in staphylococci. APMIS. 2010;118:873–877.
4. Barth RE, Vogely HC, Hoepelman AI, Peters EJ. ‘To bead or not to bead?’ Treatment of osteomyelitis and prosthetic joint-associated infections with gentamicin bead chains. Int J Antimicrob Agents. 2011;38:371–375.
5. Belisle JG, Wenke JC, Krueger CA. Return-to-duty rates among US military combat-related amputees in the global war on terror: job description matters. J Trauma Acute Care Surg. 2013;75:279–286.
6. Berdal JE, Skramm I, Mowinckel P, Gulbrandsen P, Bjornholt JV. Use of rifampicin and ciprofloxacin combination therapy after surgical débridement in the treatment of early manifestation prosthetic joint infections. Clin Microbiol Infect. 2005;11:843–845.
7. Brady RA, Leid JG, Calhoun JH, Costerton JW, Shirtliff ME. Osteomyelitis and the role of biofilms in chronic infection. FEMS Immunol Med Microbiol. 2008;52:13–22.
8. Brown KV, Murray CK, Clasper JC. Infectious complications of combat-related mangled extremity injuries in the British military. J Trauma. 2010;69(Suppl 1):S109–115.
9. Burns TC, Stinner DJ, Mack AW, Potter BK, Beer R, Eckel TT, Possley DR, Beltran MJ, Hayda RA, Andersen RC, Keeling JJ, Frisch HM, Murray CK, Wenke JC, Ficke JR, Hsu JR. Microbiology and injury characteristics in severe open tibia fractures from combat. J Trauma Acute Care Surg. 2012;72:1062–1067.
10. Cardile AP, Sanchez CJ Jr, Samberg ME, Romano DR, Hardy SK, Wenke JC, Murray CK, Akers KS. Human plasma enhances the expression of Staphylococcal microbial surface components recognizing adhesive matrix molecules promoting biofilm formation and increases antimicrobial tolerance in vitro. BMC Res Notes. 2014;7:457.
11. Ceri H, Olson M, Morck D, Storey D, Read R, Buret A, Olson B. The MBEC Assay System: multiple equivalent biofilms for antibiotic and biocide susceptibility testing. Methods Enzymol. 2001;337:377–385.
12. Coiffier G, Albert JD, Arvieux C, Guggenbuhl P. Optimizing combination rifampin therapy for staphylococcal osteoarticular infections. Joint Bone Spine. 2013;80:11–17.
13. Coraca-Huber DC, Fille M, Hausdorfer J, Pfaller K, Nogler M. Evaluation of MBEC-HTP biofilm model for studies of implant associated infections. J Orthop Res. 2012;30:1176–1180.
14. Costerton JW. Biofilm theory can guide the treatment of device-related orthopaedic infections. Clin Orthop Relat Res. 2005;437:7–11.
15. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science. 1999;284:1318–1322.
16. De Palma L, Greco F, Ciarpaglini C, Caneva C. The mechanical properties of ‘cement-antibiotic’ mixtures. Ital J Orthop Traumatol. 1982;8:461–467.
17. del Pozo JL, Patel R. The challenge of treating biofilm-associated bacterial infections. Clin Pharmacol Ther. 2007;82:204–209.
18. Dunne WM Jr, Mason EO Jr, Kaplan SL. Diffusion of rifampin and vancomycin through a Staphylococcus epidermidis biofilm. Antimicrob Agents Chemother. 1993;37:2522–2526.
19. El Helou OC, Berbari EF, Lahr BD, Eckel-Passow JE, Razonable RR, Sia IG, Virk A, Walker RC, Steckelberg JM, Wilson WR, Hanssen AD, Osmon DR. Efficacy and safety of rifampin containing regimen for staphylococcal prosthetic joint infections treated with débridement and retention. Eur J Clin Microbiol Infect Dis. 2010;29:961–967.
20. Ellington JK, Harris M, Hudson MC, Vishin S, Webb LX, Sherertz R. Intracellular Staphylococcus aureus and antibiotic resistance: implications for treatment of staphylococcal osteomyelitis. J Orthop Res. 2006;24:87–93.
21. Forrest GN, Tamura K. Rifampin combination therapy for nonmycobacterial infections. Clin Microbiol Rev. 2010;23:14–34.
22. Gogia JS, Meehan JP, Di Cesare PE, Jamali AA. Local antibiotic therapy in osteomyelitis. Semin Plast Surg. 2009;23:100–107.
23. Gomez J, Canovas E, Banos V, Martinez L, Garcia E, Hernandez-Torres A, Canteras M, Ruiz J, Medina M, Martinez P, Canovas A, Soriano A, Clavel M. Linezolid plus rifampin as a salvage therapy in prosthetic joint infections treated without removing the implant. Antimicrob Agents Chemother. 2011;55:4308–4310.
24. Hall Snyder AD, Vidaillac C, Rose W, McRoberts JP, Rybak MJ. Evaluation of high-dose daptomycin versus vancomycin alone or combined with clarithromycin or rifampin against Staphylococcus aureus and S epidermidis in a novel in vitro PK/PD model of bacterial biofilm. Infect Dis Ther. 2014 Dec 18 [Epub ahead of print].
25. Hall-Stoodley L, Stoodley P. Evolving concepts in biofilm infections. Cell Microbiol. 2009;11:1034–1043.
26. Hamza T, Dietz M, Pham D, Clovis N, Danley S, Li B. Intra-cellular Staphylococcus aureus alone causes infection in vivo. Eur Cells Mater. 2013;25:341–350; discussion 350.
27. Han CD, Oh T, Cho SN, Yang JH, Park KK. Isoniazid could be used for antibiotic-loaded bone cement for musculoskeletal tuberculosis: an in vitro study. Clin Orthop Relat Res. 2013;471:2400–2406.
28. Henry SL, Ostermann PA, Seligson D. The prophylactic use of antibiotic impregnated beads in open fractures. J Trauma. 1990;30:1231–1238.
29. Henry SL, Ostermann PA, Seligson D. The antibiotic bead pouch technique. The management of severe compound fractures. Clin Orthop Relat Res. 1993;295:54–62.
30. Howlin RP, Brayford MJ, Webb JS, Cooper JJ, Aiken SS, Stoodley P. Antibiotic-loaded synthetic calcium sulfate beads for the prevention of bacterial colonisation and biofilm formation in periprosthetic infections. Antimicrob Agents Chemother. 2015;59:111–120.
31. Inzana JA, Schwarz EM, Kates SL, Awad HA. A novel murine model of established Staphylococcal bone infection in the presence of a fracture fixation plate to study therapies utilizing antibiotic-laden spacers after revision surgery. Bone. 2015;72:128–136.
32. Johnson EN, Burns TC, Hayda RA, Hospenthal DR, Murray CK. Infectious complications of open type III tibial fractures among combat casualties. Clin Infect Dis. 2007;45:409–415.
33. Kreis CA, Raschke MJ, Rosslenbroich SB, Tholema-Hans N, Loffler B, Fuchs T. Therapy of intracellular Staphylococcus aureus by tigecyclin. BMC Infect Dis. 2013;13:267.
34. Krueger CA, Wenke JC, Ficke JR. Ten years at war: comprehensive analysis of amputation trends. J Trauma Acute Care Surg. 2012;73:S438–444.
35. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, Rybak MJ, Talan DA, Chambers HF. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011;52:285–292.
36. McConoughey SJ, Howlin RP, Wiseman J, Stoodley P, Calhoun JH. Comparing PMMA and calcium sulfate as carriers for the local delivery of antibiotics to infected surgical sites. J Biomed Mater Res B Appl Biomater. 2014 Aug 20 [Epub ahead of print].
37. McLaren AC. Alternative materials to acrylic bone cement for delivery of depot antibiotics in orthopaedic infections. Clin Orthop Relat Res. 2004;427:101–106.
38. Moehring HD, Gravel C, Chapman MW, Olson SA. Comparison of antibiotic beads and intravenous antibiotics in open fractures. Clin Orthop Relat Res. 2000;372:254–261.
39. Molina-Manso D, del Prado G, Ortiz-Perez A, Manrubia-Cobo M, Gomez-Barrena E, Cordero-Ampuero J, Esteban J. In vitro susceptibility of Staphylococcus aureus and Staphylococcus epidermidis isolated from prosthetic joint infections. J Antibiot (Tokyo). 2012;65:505–508.
40. Napierala MA, Rivera JC, Burns TC, Murray CK, Wenke JC, Hsu JR. Infection reduces return-to-duty rates for soldiers with Type III open tibia fractures. J Trauma Acute Care Surg. 2014;77:S194–197.
41. Obst G, Gagnon RF, Harris A, Prentis J, Richards GK. The activity of rifampin and analogs against Staphylococcus epidermidis biofilms in a CAPD environment model. Am J Nephrol. 1989;9:414–420.
42. Okike K, Bhattacharyya T. Trends in the management of open fractures. A critical analysis. J Bone Joint Surg Am. 2006;88:2739–2748.
43. Owens BD, Kragh JF Jr, Macaitis J, Svoboda SJ, Wenke JC. Characterization of extremity wounds in Operation Iraqi Freedom and Operation Enduring Freedom. J Orthop Trauma. 2007;21:254–257.
44. Owens BD, Kragh JF Jr, Wenke JC, Macaitis J, Wade CE, Holcomb JB. Combat wounds in operation Iraqi Freedom and operation Enduring Freedom. J Trauma. 2008;64:295–299.
45. Palmer MP, Altman DT, Altman GT, Sewecke JJ, Ehrlich GD, Hu FZ, Nistico L, Melton-Kreft R, Gause TM 3rd, Costerton JW. Can we trust intraoperative culture results in nonunions? J Orthop Trauma. 2014;28:384–390.
46. Parker AE, Walker DK, Goeres DM, Allan N, Olson ME, Omar A. Ruggedness and reproducibility of the MBEC biofilm disinfectant efficacy test. J Microbiol Methods. 2014;102:55–64.
47. Parra-Ruiz J, Vidaillac C, Rose WE, Rybak MJ. Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm. Antimicrob Agents Chemother. 2010;54:4329–4334.
48. Patel R. Biofilms and antimicrobial resistance. Clin Orthop Relat Res. 2005;437:41–47.
49. Sanchez CJ Jr, Mende K, Beckius ML, Akers KS, Romano DR, Wenke JC, Murray CK. Biofilm formation by clinical isolates and the implications in chronic infections. BMC Infect Dis. 2013;13:47.
50. Stoodley P, Ehrlich GD, Sedghizadeh PP, Hall-Stoodley L, Baratz ME, Altman DT, Sotereanos NG, Costerton JW, Demeo P. Orthopaedic biofilm infections. Curr Orthop Pract. 2011;22:558–563.
51. Tan H, Peng Z, Li Q, Xu X, Guo S, Tang T. The use of quaternised chitosan-loaded PMMA to inhibit biofilm formation and downregulate the virulence-associated gene expression of antibiotic-resistant staphylococcus. Biomaterials. 2012;33:365–377.
52. Tang HJ, Chen CC, Zhang CC, Su BA, Li CM, Weng TC, Chiang SR, Ko WC, Chuang YC. In vitro efficacy of fosfomycin-based combinations against clinical vancomycin-resistant Enterococcus isolates. Diagn Microbiol Infect Dis. 2013;77:254–257.
53. Tennent DJ, Wenke JC, Rivera JC, Krueger CA. Characterisation and outcomes of upper extremity amputations. Injury. 2014;45:965–969.
54. Urabe K, Naruse K, Hattori H, Hirano M, Uchida K, Onuma K, Park HJ, Itoman M. In vitro comparison of elution characteristics of vancomycin from calcium phosphate cement and polymethylmethacrylate. J Orthop Sci. 2009;14:784–793.
55. Valour F, Trouillet-Assant S, Rasigade JP, Lustig S, Chanard E, Meugnier H, Tigaud S, Vandenesch F, Etienne J, Ferry T, Laurent F. Staphylococcus epidermidis in orthopedic device infections: the role of bacterial internalization in human osteoblasts and biofilm formation. PloS One. 2013;8:e67240.
56. Varaldo PE, Debbia E, Schito GC. In vitro activities of rifapentine and rifampin, alone and in combination with six other antibiotics, against methicillin-susceptible and methicillin-resistant staphylococci of different species. Antimicrob Agents Chemother. 1985;27:615–618.
57. Vergidis P, Schmidt-Malan SM, Mandrekar JN, Steckelberg JM, Patel R. Comparative activities of vancomycin, tigecycline and rifampin in a rat model of methicillin-resistant Staphylococcus aureus osteomyelitis. J Infect. 2015 Jan 7 [Epub ahead of print].
58. Wenke JC, Guelcher SA. Dual delivery of an antibiotic and a growth factor addresses both the microbiological and biological challenges of contaminated bone fractures. Exp Opin Drug Deliv. 2011;8:1555–1569.
59. Zheng Z, Stewart PS. Penetration of rifampin through Staphylococcus epidermidis biofilms. Antimicrob Agents Chemother. 2002;46:900–903.
60. Zimmerli W, Moser C. Pathogenesis and treatment concepts of orthopaedic biofilm infections. FEMS Immunol Med Microbiol. 2012;65:158–168.